

MOLECULAR MODIFICATION ASSAYS

Cross-References

This application is based upon and claims benefit under 35 U.S.C. § 119(e) of the following U.S. provisional patent applications, which are incorporated herein by reference: Serial No. 60/200,594, filed April 28, 2000; Serial No. 60/223,642, filed August 8, 2000; and Serial No. 60/241,032, filed October 17, 2000.

This application is a continuation of and claims benefit under 35 U.S.C. § 120 of the following patent applications, which are incorporated herein by reference: PCT Patent Application Serial No. PCT/US00/16025, filed June 9, 2000; and U.S. Patent Application Serial No. 09/596,444, filed June 19, 2000.

This application incorporates by reference the following U.S. patents: No. 5,843,378, issued December 1, 1998; No. 6,965,381, issued October 12, 1999; No. 6,071,748, issued June 6, 2000; and No. 6,097,025, issued August 1, 2000.

This application also incorporates by reference the following U.S. patent applications: Serial No. 08/840,553, filed April 14, 1997; Serial No. 09/118,141, filed July 16, 1998; Serial No. 09/144,578, filed August 31, 1998; Serial No. 09/156,318, filed September 18, 1998; Serial No. 09/349,733, filed July 8, 1999; Serial No. 09/478,819, filed January 5, 2000; Serial No. 09/596,444, filed June 19, 2000; Serial No. 09/626,208, filed July 26, 2000; Serial No. 09/643,221, filed August 18, 2000; Serial No. 09/710,061, filed November 10, 2000; Serial No. 09/722,247, filed November 24, 2000; Serial No. 09/733,370, filed December 8, 2000; Serial No. 09/759,711, filed January 12, 2001;

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Serial No. 09/765,869, filed January 19, 2001; Serial No. 09/765,874, filed January 19, 2001; Serial No. 09/766,131, filed January 19, 2001; Serial No. 09/767,316, filed January 22, 2001; Serial No. 09/767,434, filed January 22, 2001; Serial No. 09/767,579, filed January 22, 2001; Serial No. 09/767,583, filed January 22, 2001; Serial No. 09/768,661, filed January 23, 2001; Serial No. 09/768,742, filed January 23, 2001; Serial No. 09/768,765, filed January 23, 2001; Serial No. 09/770,720, filed January 25, 2001; Serial No. 09/770,724, filed January 25, 2001; Serial No. 09/777,343, filed February 5, 2001; Serial No. 09/813,107, filed March 19, 2001; Serial No. 09/815,932, filed March 23, 2001; and Serial No. _____, filed April 16, 2001 entitled *Arc Lamp Power Supply*, and naming David P. Stumbo as inventor.

This application also incorporates by reference the following U.S. provisional patent applications: Serial No. 60/178,026, filed January 26, 2000; Serial No. 60/222,222, filed August 1, 2000; Serial No. 60/244,012, filed October 27, 2000; Serial No. 60/250,681, filed November 30, 2000; Serial No. 60/250,683, filed November 30, 2000; and Serial No. 60/267,639, filed February 10, 2001.

This application also incorporates by reference the following publications: Richard P. Haugland, Handbook of Fluorescent Probes and Research Chemicals (6th ed. 1996); Joseph R. Lakowicz, Principles of Fluorescence Spectroscopy (2nd Edition 1999); and Bob Sinclair, Everything's Great When It Sits on a Chip: A Bright Future for DNA Arrays, 13 THE SCIENTIST, May 24, 1999, at 18.

Field of the Invention

The invention relates to assays for molecular modifications. More particularly, the invention relates to assays for detecting molecular modifications such as phosphate modifications and the presence and/or activity of enzymes and other agents involved in facilitating or otherwise regulating such modifications.

Background of the Invention

The physiological modification of molecules and supramolecular assemblies plays a major role in the structure and regulation of biological systems. These modifications may include phosphorylation, cyclization, glycosylation, acylation, and/or sulfation, among others, and the modified molecules may include polypeptides, nucleic acids, and/or lipids, among others. The importance of modifications is particularly evident in the cell-signaling pathway, in which extracellular and intracellular substances related by phosphate modifications such as phosphorylation and cyclization influence the position, nature, and activity of cells.

Figure 1 is a schematic view of a representative cell-signaling pathway 100. Here, signaling cells 102 produce signal substances 104_{a,b} that interact with target cells 106 to effect a response in the target cells. These responses may be short term, such as glycogen breakdown or muscle contraction, among others. These responses also may be long term, such as growth, differentiation, reproduction, and/or apoptosis, among others. Generally, these responses are brought about by increasing, decreasing, and/or maintaining enzyme activity in the target cells.

Signaling cells 102 are cells capable of producing a signal (substance) that can effect a specific response in another (target) cell. The signaling cells may be components of an endocrine, paracrine, or nervous system. The endocrine system is an organism-wide control system that regulates body function using hormones released by endocrine organs into the bloodstream. The endocrine organs include the pituitary gland, thyroid gland, parathyroid glands, adrenal glands, thymus gland, pineal body, pancreas, ovaries, testes, and kidneys. The paracrine system is a local control system that regulates nearby cells using local mediators released into the extracellular medium. The nervous system is a specialized control system that regulates specific cells using electrical impulses and neurotransmitters.

Signal substances 104_{a,b} are substances through which a signaling cell may communicate with target cells, evoking a specific response. Signal substances may act as hormones, local mediators, and/or neurotransmitters, among others. Signal substances may take the form of proteins, small peptides, amino acids, nucleotides, steroids (e.g., cortisol, steroid sex hormones, vitamin D), retinoids, fatty acid derivatives, and dissolved gases (e.g., nitric oxide (NO) and carbon monoxide (CO)), among others.

Target cells 106 are cells capable of responding to a specific signal substance produced by a signaling cell. The ability to respond may depend on the cell and on the signal substance. For example, the signal substance thyroxine from the thyroid gland may evoke a response in nearly all cells, whereas the signal substance progesterone from the ovary may evoke a response only in specific cells in the lining of the uterus. The target response may include kinase activity, GTP binding, and/or cyclic nucleotide production.

The ability of a cell to respond to a given signal substance generally is determined by whether the cell includes a receptor for the signal substance. Here, a receptor is any molecule or supramolecular assembly capable of specifically binding a signal substance and initiating a response in a target cell. Representative receptors include cell-surface receptors 110 located on the surface of the target cell and intracellular receptors 112 located within the cytosol 114 or nucleus 116 of the target cell.

The nature of the response initiated by binding of a signal substance is determined by the intracellular machinery to which the receptor is operatively coupled. For example, binding of the neurotransmitter acetylcholine to identical receptors in heart muscle cells and secretory cells causes muscle relaxation in the heart muscle cells and secretion in the secretory cells, due to differences in the associated intracellular machinery.

The remainder of this section examines (1) the receptor mechanisms that cells use to bind signal substances and to communicate this binding to the cell interior, (2) the intracellular pathways that cells use for regulation, (3) the effects of errors in cell-signaling pathways, and (4) selected shortcomings of current cell-signaling assays.

1. Receptor Mechanisms

Target cells generally have receptors capable of specifically binding specific signal substances, including cell-surface receptors and/or intracellular receptors, as described above. Cell-surface receptors are more common and include (A) G-protein-linked receptors, (B) enzyme-linked receptors, and (C) ion-channel-linked receptors. These receptors typically bind large and/or water-soluble signal substances, such as many peptide hormones. Intracellular receptors are less common and include (A) guanylyl

cyclase and (B) ligand-activated gene regulatory proteins. These receptors typically bind small and/or water-insoluble signal substances, such as steroid hormones, thyroid hormones, retinoids, vitamin D, and NO.

Figure 2 is a schematic view of a representative G-protein-linked cell-surface receptor mechanism 130 that includes a receptor protein 132, a G-protein 134, and a target protein 136. These proteins may be positioned on or within the plasma membrane 138 of a target cell. In use, a specific signal substance 140 binds to a signal-substance binding site 142 on the extracellular side 144 of the receptor protein and thereby creates, exposes, or otherwise activates (*) a G-protein binding site 146 on the intracellular side 148 of the receptor protein. The G-protein then binds to the G-protein binding site on the receptor protein and thereby creates, exposes, or otherwise activates (*) a target-protein binding site 150 on the G-protein. The G-protein then dissociates from the receptor protein, binds (via the target-protein binding site) to the target protein, and activates (*) the target protein. Activation and deactivation of the G-protein may involve binding of a guanosine triphosphate (GTP) molecule and dephosphorylation of the GTP molecule, respectively. The receptor protein may belong to a large superfamily of homologous, seven-pass transmembrane proteins. These seven-pass proteins consist of a single polypeptide chain that crosses the membrane seven times, with an extracellular signal-substance binding portion and an intracellular catalytic portion. The G-protein may be trimeric, consisting of three polypeptide chains-- α , β , and γ --that associate and dissociate during signaling. The target protein may consist of an enzyme or ion channel, among others. In particular, the target protein may be an enzyme that modulates the presence or

activity of second messengers within the cell. These second messengers (also known as intracellular messengers or intracellular mediators) may bind allosterically to specific cellular proteins to alter their conformation and hence their activity. These second messengers include adenosine 3',5'-cyclic monophosphate (cAMP) and calcium (Ca^{2+}).

5 In the cAMP pathway, the target protein may be adenylyl cyclase (also known as adenylyl cyclase), and the G-protein may be a stimulatory G-protein (G_s) that activates the adenylyl cyclase to make cAMP, or an inhibitory G protein (G_i) that inhibits the adenylyl cyclase to prevent it from making cAMP. The cAMP produced by the adenylyl cyclase activates cAMP-dependent protein kinase (A-kinase), which is a serine/threonine kinase that in turn activates or inhibits other enzymes to effect a physiological response. For example, in connection with glycogen metabolism, A-kinase may inhibit glycogen synthase to shut down glycogen synthesis, and simultaneously activate phosphorylase kinase that in turn activates glycogen phosphorylase to break down glycogen. A variety of signal substances use cAMP as a second messenger, including calcitonin, chorionic gonadotropin, corticotropin, epinephrine, follicle-stimulating hormone, glucagon, luteinizing hormone, lipotropin, melanocyte-stimulating hormone, norepinephrine, parathyroid hormone (PTH), thyroid-stimulating hormone, and vasopressin. The level of cAMP may be reduced by phosphodiesterases (PDEs), and the activity of kinases may be reversed by phosphatases, as described below.

20 In the Ca^{2+} pathway, the target protein may be a phospholipase with specificity for a phosphoinositide (i.e., inositol phospholipid), and the G-protein may be G_q , which activates the phospholipase to cleave the phosphoinositide to produce an intermediate

that releases Ca^{2+} from the endoplasmic reticulum. For example, the phospholipase phosphoinositide-specific phospholipase C (phospholipase C- β) cleaves the phosphoinositide phosphatidylinositol 4,5-bisphosphate (PIP_2) to produce the second messengers inositol triphosphate (IP_3) and diacylglycerol. The inositol triphosphate is water soluble and diffuses to the endoplasmic reticulum (ER), where it releases Ca^{2+} from the ER by binding to IP_3 -gated Ca^{2+} -release channels in the ER membrane. The diacylglycerol is membrane bound and may be cleaved to form the second messenger arachidonic acid or may activate the Ca^{2+} -dependent serine/threonine kinase protein kinase C that in turn activates or inhibits other enzymes to effect a response. A variety of signal substances use Ca^{2+} as a second messenger, including acetylcholine, thrombin, and vasopressin.

Figure 3 is a schematic view of a representative enzyme-linked cell-surface receptor mechanism 170 that includes a receptor protein 172 positioned across the plasma membrane 174 of a target cell. The receptor protein includes a signal-substance binding site 176 on the extracellular side 178 of the membrane and a catalytic portion 180 on the intracellular side 182 of the membrane. (In some cases, the catalytic portion of the receptor may be replaced or augmented by a separate enzyme directly associated with the receptor protein.) In use, a specific signal substance 184 binds to the signal-substance binding site, initiating a series of events (such as dimerization and concomitant autophosphorylation of the receptor proteins) that activates (*) the catalytic portion of the receptor. The receptor protein may belong to one of at least five classes of single-pass transmembrane proteins: (A) receptor guanylyl cyclases, which catalyze the production

of guanosine 3',5'-cyclic monophosphate (cGMP) in the cytosol; (B) receptor tyrosine kinases, which phosphorylate specific tyrosine residues on some intracellular proteins, (C) tyrosine-kinase-associated receptors, which associate with proteins that phosphorylate specific tyrosine residues on some intracellular proteins; (D) receptor
5 tyrosine phosphatases, which dephosphorylate specific tyrosine residues on some intracellular proteins, and (E) receptor serine/threonine kinases, which phosphorylate specific serine or threonine residues on some intracellular proteins. Some of these receptors are described below in more detail.

The signal substance also may bind to intracellular receptors, such as guanylyl cyclase. This enzyme produces cGMP from GTP, which then acts as a second messenger much like cAMP. As described above, cGMP also may be produced by enzyme-linked cell-surface receptors. cGMP is present in most tissues at levels 1/10 to 1/100 those of cAMP. A variety of compounds increase cGMP levels in cells, including (1) the hormones acetylcholine, insulin, and oxytocin, (2) the guanylate cyclase stimulators (and vasodilators) nitroprusside, nitroglycerin, sodium nitrate, and nitric oxide, (3) chemicals such as serotonin and histamine, and (4) peptides such as atrial natriuretic peptide (ANP) that relax smooth muscle.

The level of cyclic nucleotides such as cAMP and cGMP may be controlled by specialized enzymes known as phosphodiesterases (PDEs). These enzymes catalyze the
20 hydrolysis of the 3'-ester bond of cAMP and/or cGMP to form the corresponding uncyclized nucleotide monophosphates AMP and GMP, respectively. More than 30 human PDEs are known, and there is great interest in the pharmaceutical industry in

finding inhibitors for PDEs for a broad range of potential therapeutic applications. A selective inhibitor of PDE-5 has been commercialized as the drug Viagra™ (i.e., Sildenafil) for the treatment of male erectile dysfunction. Moreover, several PDE-4 inhibitors are in clinical trials as anti-inflammatory drugs for the treatment of diseases such as asthma

2. Intracellular Signaling Pathways

Target cells may have intracellular signaling pathways capable of specifically binding signal substances, including cell-surface receptors and intracellular receptors, as described above. These pathways may include (1) a phosphorylation pathway involving ATP/ADP, and (2) a GTP-binding pathway involving GTP/GDP.

Figure 4A is a schematic view of a representative portion of a phosphorylation pathway. Phosphorylation is the predominant mechanism used to regulate protein activity in eucaryotic cells. In phosphorylation, a phosphate group (P) is reversibly attached to the side chain of an amino acid in a protein. The attached phosphate group may cause structural changes in the protein, for example, due to electrostatic interactions between the negative charges on the phosphate group and positive charges on the side chains of nearby amino acids. These structural changes may affect the activity of the phosphorylated protein, enhancing or inhibiting its function.

Specialized enzymes control phosphorylation in cells. In particular, protein kinase enzymes transfer phosphate groups to proteins, and protein phosphatase enzymes remove phosphate groups from proteins. Protein kinases and protein phosphatases are found in

great variety in eucaryotic cells: a single cell may contain more than 100 different kinases, and one percent of genes may code for kinases.

There are two major categories of protein kinases: (1) serine/threonine (S/T) kinases, and (2) tyrosine kinases. The S/T kinases function by selectively phosphorylating serine and threonine side chains on substrate proteins or peptides. These kinases include cyclic AMP-dependent kinase (A-kinase), cyclic GMP-dependent kinase (G-kinase), protein kinase C (C-kinase), Ca^{2+} -calmodulin-dependent kinase (CaM-kinase), phosphorylase kinase, MAP kinase, and TGF- β receptor, among others. The S/T kinases are predominantly cytosolic. The tyrosine kinases function by selectively phosphorylating tyrosine side chains on substrate proteins or peptides. These kinases include the receptor kinases for epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), insulin, insulinlike growth factor-1 (IGF-1), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and macrophage colony stimulating factor (M-CSF). These kinases also include the nonreceptor kinases associated with the tyrosine-kinase-associated receptors, such as the Src family (Src, Yes, Fgr, Fyn, Lck, Lyn, Hck, and Blk) and Janus family (JAK1, JAK2, and Tyk2) kinases. The tyrosine kinases are predominantly membrane bound. A few kinases function by selectively phosphorylating threonine and tyrosine side chains on substrate proteins or peptides. These kinases include the mitogen-activated protein (MAP) kinase-kinase.

Figure 4B is a schematic of a representative portion of a GTP-binding pathway. The GTP-binding pathway generally resembles the phosphorylation pathway in that each

pathway involves transfer of a phosphate group to a protein. However, in the GTP-binding pathway, the protein gains a phosphate group by exchanging a bound GDP for a bound GTP, whereas in the phosphorylation pathway, the protein gains a phosphate group by covalent addition of the phosphate group to a serine, threonine, or tyrosine by a kinase enzyme. The binding of a GTP to a GTP-binding protein may cause structural changes in the protein that in turn affect the activity of the protein. Examples of GTP-binding proteins include the trimeric G-proteins described above and the Ras superfamily of monomeric GTPases. The Ras proteins are activated by release of bound GDP and binding of GTP stimulated by guanine-nucleotide releasing proteins (GNRPs). The Ras proteins are inactivated by hydrolysis of the bound GTP by GTPase-activating proteins (GAPs).

Figure 5 is a schematic view of a representative portion of a second messenger pathway that may follow the receptor activation shown in Figure 4. Specifically, Figure 5 shows the production of cyclic nucleotides by activated receptor cyclases such as adenylyl cyclase and guanylyl cyclase and the degradation of cyclic nucleotides to form the corresponding uncyclized nucleotide monophosphates by phosphodiesterases and/or other mechanisms.

A physiological response may require stimulation by only a single type of signal substance, or may require stimulation by two or more types of signal substances. The latter mechanism permits finer tuning of the physiological response through signal integration. For example, a protein may be activated only by phosphorylation by two different kinases, themselves activated by binding of two different signal substances to

two different receptors. Alternatively, a protein may be activated only by concurrent phosphorylation and GTP binding, or by binding of two subunits whose binding is contingent on phosphorylation by separately activated kinases.

3. Effects of Errors

Errors in the signal transduction and regulation pathways described above can cause cancer and other diseases. Indeed, a primary cause of cancer is a mutation that makes a stimulatory gene product hyperactive, converting a proto-oncogene into an oncogene. The primary classes of known proto-oncogenes include the following cell-signaling proteins: (1) growth-factor receptors acting via tyrosine kinases, (2) GTP binding proteins, (3) membrane/cytoskeleton-associated tyrosine kinases, (4) cytoplasmic tyrosine kinases, (5) steroid-type growth-factor receptors, and (6) S/T kinases. Consequently, cell-signaling proteins have become important subjects of research and drug development.

4. Selected Shortcomings of Current Assays

Assays that determine the presence and/or activity of cell-signaling components are important tools in life sciences research, including high-throughput screening. Unfortunately, current assays have a number of shortcomings.

The presence and activity of kinases, for example, can be determined using assays capable of detecting phosphorylated amino acids. In a standard kinase assay, radioactive ATP and an appropriate protein substrate are added to a sample. If the sample includes kinases, radioactive phosphate groups will be transferred from the radioactive ATP to the protein substrate. The presence and activity of kinases can be determined by assaying the

amount of radioactive protein substrate, for example, using heterogeneous methods such as a filter plate that involve separating the protein substrate and radioactive ATP, or homogeneous methods such as a scintillation proximity assay for detecting radioactive decay. Unfortunately, both approaches involve radioactivity, presenting a short-term safety hazard for the assay operator and a long-term storage and disposal problem.

In an alternative kinase assay, ATP, a luminescent protein, and an antibody against a phosphorylated form of the luminescent protein are added to a sample. If the sample includes kinases, the kinases will transfer phosphate groups from the ATP to the protein, the antibody will bind to the phosphorylated protein, and the luminescence polarization of the protein will increase (because its rotational mobility will decrease). Unfortunately, the binding of antibodies is very target specific, so that in general a different antibody will be needed for each substrate (depending on the sequence of the substrate, including whether a tyrosine, serine, or threonine is to be phosphorylated). This shortcoming is especially significant for serines and threonines. Thus, a different antibody may be needed for each of the many kinases, depending on the polypeptide sequences of the corresponding substrates. Yet, suitable antibodies may be unavailable for many substrates and kinases, especially for poorly studied or previously unstudied kinases, or take several months or more to prepare.

Significantly, assays for other cell-signaling components (such as phosphatases, phosphodiesterases, and/or cyclases) may have similar shortcomings, such as the use of radioactive reagents, if the assays exist at all. Moreover, these assays may have slow time courses and unstable endpoints that require precise timing of assay readouts. Thus, there

is a need for improved assays for detecting enzyme activity, and in particular the presence and activity of cell-signaling components.

Summary of the Invention

The invention provides assays for detecting molecular modifications such as phosphate modifications and the presence and/or activity of enzymes and other agents involved in facilitating or otherwise regulating such modifications.

Brief Description of the Drawings

Figure 1 is a schematic view of a cell-signaling pathway.

Figure 2 is a schematic view of a G-protein-linked cell-surface receptor mechanism that includes a receptor protein, a G-protein, and a target protein, all associated with the plasma membrane of a target cell.

Figure 3 is a schematic view of an enzyme-linked cell-surface receptor mechanism that includes a receptor protein positioned across the plasma membrane of a target cell.

Figure 4 is a schematic view of two common intracellular signaling pathways: (A) a phosphorylation pathway involving ATP/ADP, and (B) a GTP-binding pathway involving GTP/GDP.

Figure 5 is a schematic view of a representative portion of a second messenger pathway that may follow the receptor activation shown in Figure 4.

Figure 6 is a schematic view of species and/or reactions that may be analyzed using assays provided by the invention.

Figure 7 is a flowchart showing steps that may be used alone, together, or in combination with other steps to construct assays according to various aspects of the invention.

Figure 8 is a graph showing the effects of incubating 10 nM TK-1 tracer with 5 different concentrations of MM-Ga.

Figure 9 is a graph showing a dose-response curve for TK-1 calibrator, with 10 nM TK-1 tracer and 1.6 nM (estimated) MM-Ga.

Figure 10 is a bar graph showing results from an endpoint assay for PKA activity with MM-Ga under the following conditions: (1) reaction with enzyme, with MM-Ga; (2) reaction with enzyme, without MM-Ga; (3) reaction without enzyme, with MM-Ga; and (4) reaction without enzyme, without MM-Ga.

Figure 11 is a graph showing a time-course assay of PKA activity with MM-Ga performed under the reaction conditions of Figure 10.

Figure 12 is a graph showing a time-course assay of PKA activity with a $G\alpha^{3+}$ -coated plate.

Figure 13 is a bar graph showing results from an end-point study for cGMP PDE activity using MANT-cGMP and MM-Ga under the following conditions: (1) reaction with enzyme, with MM-Ga, (2) reaction with enzyme, without MM-Ga (3) reaction without enzyme, with MM-Ga (4) reaction without enzyme, without MM-Ga.

Figure 14 is a graph showing results from a time-course study conducted using the system of Figure 13.

Figure 15 is a graph showing results from a time-course study for cGMP PDE activity using fluorescein-cGMP and MM-GA.

Figure 16 is a graph showing an IC50 measurement of Zaprinast using the system of Figure 15.

5 Figure 17 is a graph showing the detection of PDE 4 activity using a fluorescein-labeled cAMP substrate.

Figure 18 is a graph showing the detection of PDE 5 activity using a fluorescein-labeled cGMP substrate using the conditions of Figure 17.

Figure 19 is a graph showing the detection of PDE 1 activity using fluorescein-labeled cAMP and fluorescein-labeled cGMP substrates under the conditions of Figure 17.

Definitions

The various technical terms used herein generally have the meanings that are commonly recognized by those skilled in the art. However, the following terms may have additional and/or alternative meanings, as described below:

Cyclization / decyclization – the formation or degradation of a ring connecting a phosphate group and a nucleoside in a nucleotide. A common cyclization forms cAMP and cGMP from ATP and GTP, respectively, by removing two phosphate groups from the nucleotide triphosphates and joining the “free” end of the remaining phosphate group to the sugar in the remaining nucleotide monophosphate. A common decyclization reaction degrades the ring to form AMP and GMP from cAMP and cGMP, respectively.

Immunoglobulin – a group of typically large glycoproteins secreted by plasma cells in vertebrates that function as antibodies in the immune response by binding to specific antigens.

Luminescent – capable of, suitable for, or exhibiting luminescence, which is the emission of light by sources other than a hot, incandescent body. Luminescence is caused by electronic transitions within a luminescent substance (or luminophore) from more energetic to less energetic states. Among several types are chemiluminescence, electrochemiluminescence, electroluminescence, photoluminescence, and triboluminescence, which are produced by chemical reactions, electrochemical reactions, electric discharges, absorption of light, and the rubbing or crushing of crystals, respectively. Molecules may be intrinsically and/or extrinsically luminescent, meaning that they are luminescent on their own or luminescent due to covalent and/or noncovalent association with another molecule that is luminescent. Exemplary luminescent molecules and mechanisms for producing luminescent molecules are described in U.S. Patent Application Serial No. 09/815,932, filed March 23, 2001, which is incorporated herein by reference.

Nucleotide – a compound comprising a nucleoside and a phosphate group, some of which function as cell regulators and some of which function as the basic constituent of DNA and RNA. A nucleoside in turn is a compound comprising a sugar, such as ribose or deoxyribose, and a purine or pyrimidine base, such as adenine, cytosine, guanine, thymine, or uracil. Nucleotides are named according to the identities of their

constituent bases and sugars, the number of their constituent phosphates, and the presence or absence of cyclization. Suitable nucleotides are listed in the following table:

<i>Nucleotide</i>	<i>Abbreviation</i>
Adenosine cyclic monophosphate	cAMP
Cytidine cyclic monophosphate	cCMP
Guanosine cyclic monophosphate	cGMP
Thymidine cyclic monophosphate	cTMP
Uridine cyclic monophosphate	cUMP
Adenosine monophosphate	AMP
Cytidine monophosphate	CMP
Guanosine monophosphate	GMP
Thymidine monophosphate	TMP
Uridine monophosphate	UMP

Phosphorylation / dephosphorylation – the introduction or removal of a phosphate group to or from an organic molecule such as a polypeptide. Phosphorylation is a versatile posttranslational modification that is a recurrent theme for regulation of enzyme activity and signal transduction pathways.

Polypeptide - a polymer comprising two or more amino acid residues linked together by covalent bonds, typically from amino end to carboxyl end by peptide bonds, and modifications and complexes thereof. Polypeptides generally include peptides and/or proteins, among others. Here, peptide generally refers to smaller polypeptides (e.g., less than about 100, 50, 20, or 10 amino acids, among others), and protein generally refers to larger polypeptides, and complexes thereof, possibly modified by other organic or inorganic conjugated chemical groups, such as phosphates, sugars, and so on. Polypeptides may include straight chains and/or branched chains, among others. Suitable amino acids are listed in the following table:

<i>Amino acid</i>	<i>Three-letter abbreviation</i>	<i>One-letter abbreviation</i>
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Asparagine or aspartic acid	Asx	B
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glutamine or glutamic acid	Glx	Z
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

Specific binding – binding to a specific binding partner to the exclusion of binding to most other moieties. Specific binding can be characterized by a binding coefficient. Generally, specific binding coefficients range from 10^{-4} M to 10^{-12} M and lower, and preferred specific binding coefficients range from 10^{-8} or 10^{-9} M to 10^{-12} M and lower.

Detailed Description

The invention provides assays for detecting molecular modifications and the presence and/or activity of enzymes and other agents involved in facilitating or otherwise regulating such modifications. The modifications may include among others phosphate

modifications, such as the phosphorylation and dephosphorylation of molecules such as polypeptides and the cyclization and decyclization of molecules such as nucleotides. The enzymes may include among others enzymes involved in performing and/or regulating phosphorylation, dephosphorylation, cyclization, and decyclization modifications, such as kinases, phosphatases, cyclases, and phosphodiesterases (PDEs), respectively. The assays may include among others luminescence assays, such as luminescence polarization, luminescence resonance energy transfer, and/or luminescence intensity. The assays provided by the invention may be useful in a variety of applications, including without limitation life science research, drug research, accelerated drug discovery, assay development, and high-throughput screening, among others.

1. Overview

Figure 6 shows species and/or reactions that may be analyzed using assays provided by the invention. The species include reactant and product A and A*, respectively, enzymes E_{AA^*} and E_{A^*A} , and/or enzyme modulators $M_{E_{AA^*}}$ and $M_{E_{A^*A}}$, among others. The assays may be used to analyze the presence and/or quantity of A and/or A*. Alternatively, or in addition, the assays may be used to analyze the presence and/or activity of E_{AA^*} , E_{A^*A} , $M_{E_{AA^*}}$, and/or $M_{E_{A^*A}}$. Quantity refers generally to amount, which may be defined intrinsically and/or extrinsically, for example, using concentration and/or number or mass, respectively. Activity refers generally to rate, which may be defined as the rate of substrate consumption and/or product formation per time. Here, quantity and/or amount may be used so as to encompass the simple presence of

components, and activity and/or rate may be used so as to encompass the simple presence of activity.

A and A* generally comprise any two species related by a modification (denoted by the presence or absence of *). A and A* may include molecules and assemblies of molecules such as polypeptides and/or nucleotides, among others. The modification may include phosphate modifications such as phosphorylation, dephosphorylation, cyclization, and/or decyclization, among others, and nonphosphate modifications such as nonphosphate posttranslational modifications of polypeptides, among others. A and A* may be related as substrate and product in a reaction, such as an enzyme-catalyzed reaction. Thus, depending on the direction of the reaction, A and A* in a phosphate modification may be a phosphorylated polypeptide, a nonphosphorylated polypeptide, a cyclized nucleotide, or a noncyclized nucleotide, among others. In some embodiments, A and/or A* may include components intended to facilitate detection of binding between A or A* and BP, such as a luminophore, a quencher, an energy transfer partner, and the like.

BP generally comprises any binding partner capable of binding specifically to A or A* (i.e., the modified species or the unmodified species) but not to both. BP may include any binding partner having the specified binding properties that does not include a polypeptide and/or an immunoglobulin, and/or a functional portion or fragment thereof. Alternatively, or in addition, BP may include one or more metal ions, including dicationic, tricationic, and polycationic metal ions, among others. Suitable dicationic metal ions include iridium (Ir^{2+}), osmium (Os^{2+}), platinum (Pt^{2+}), rhenium (Re^{2+}), and

ruthenium (Ru^{2+}), among others. Suitable tricationic metal ions include including aluminum (Al^{3+}), chromium (Cr^{3+}), iron (Fe^{3+}), gallium (Ga^{3+}), manganese (Mn^{3+}), scandium (Sc^{3+}), titanium (Ti^{3+}), vanadium (V^{3+}), and/or yttrium (Y^{3+}), among others. Preferred metal ions include aluminum, iron, and gallium. The metal ions may interact with or otherwise be involved in or required for binding with the modification on A or A*, such as the phosphate group on a phosphorylated protein or a noncyclized nucleotide. Alternatively, or in addition, BP may include one or more charged portions to facilitate or otherwise participate in the binding reaction with A or A*, particularly charged portions that are immobilized relative to BP. Alternatively, or in addition, BP may bind to a substrate such as A or A* only if it is phosphorylated, where the binding between the substrate and the binding partner is substantially nonspecific with respect to the structure of the substrate aside from any phosphate groups. Thus, the binding may occur substantially without regard to the target amino acid or surrounding amino acid sequence in a phosphorylation/dephosphorylation assay, or the base or nucleoside in a cyclization/decyclization assay. Alternatively, or in addition, BP may include a macromolecule and/or a particle. Here, particles include nanoparticles and microparticles, among others, where nanoparticles are particles with at least one dimension less than about 100 nm, and microparticles are particles with dimensions between about 100 nm and about 10 μm . Alternatively, or in addition, BP may be linked to an associated solid phase, such as a bead, membrane, or sample holder, among others. The link may be formed using any suitable mechanism, including hydrogen bonding, ionic bonding, electrostatic binding, hydrophobic interactions, Van der Waals interactions, and/or

covalent attachment, among others. In some embodiments, BP may include components intended to facilitate detection of binding between BP and A or A*, such as a luminophore, a quencher, an energy transfer partner, and the like.

E_{AA^*} and E_{A^*A} generally comprise any enzymes or other catalysts capable of facilitating reactions converting A to A* and A* to A, respectively. E_{AA^*} and E_{A^*A} may include among others enzymes such as kinases and phosphatases, which catalyze the addition and removal of phosphate groups to and from polypeptides, respectively. E_{AA^*} and E_{A^*A} also may include enzymes such as cyclases and phosphodiesterases, which catalyze the cyclization and decyclization of nucleotides, respectively.

$M_{E_{AA^*}}$ and $M_{E_{A^*A}}$ generally comprise any modulators or other agents capable of modulating or otherwise affecting the activity of E_{AA^*} and E_{A^*A} , respectively. The modulator may be a change in environmental condition, such as a change in sample temperature, but more typically is an enzyme or other reagent added to the sample. The modulator may be a chemical reagent, such as an acid, base, metal ion, organic solvent, and/or other substance intended to effect a chemical change in the sample. Alternatively, or in addition, the modulator may have or be suspected to have a biological activity or type of interaction with a given biomolecule, such as an enzyme, drug, oligonucleotide, nucleic acid polymer, peptide, protein, and/or other biologically active molecule. The modulator may include an agonist or inhibitor capable of promoting or inhibiting, respectively, the activity of the modulated enzyme. For example, in a cyclic nucleotide assay, preferred agonists include forskolin and isoproterenol, and preferred inhibitors include propranolol and Zaprinas.

2. Assays

Figure 7 shows several steps that may be used alone, together, or in combination with other steps to construct assays according to various aspects of the invention. These steps may include (1) contacting at least one member of a pair of molecules or other entities related by a modification as described above with a binding partner capable of binding one of the pair of molecules but not the other as described above, (2) detecting a response indicative of the extent of binding between the at least one member of the pair and the binding partner, and (3) correlating the response with the extent of modification, or with the presence and/or activity of an enzyme that affects the modification. The assays further may include contacting the at least one member with the enzyme before and/or after the steps of contacting, detecting, and correlating. The assays further may include contacting the at least one member and the enzyme with a candidate compound such as a putative modulator before and/or after the step of contacting the at least one member with the enzyme, and determining the ability of the candidate compound to promote or inhibit the modification by its effects on the extent of binding. Alternatively, or in addition, the assays further may include washing the sample including the at least one member and the binding partner to remove any member of the pair not bound to the binding partner prior to the step of detecting the extent of binding. In some embodiments, the assays may include repeating the steps of contacting, detecting, and/or correlating for the same sample and/or a plurality of different samples. For example, the assays may involve providing a sample holder having a plurality of sample sites supporting a corresponding plurality of samples, and sequentially and/or simultaneously repeating the

steps of contacting, detecting, and/or correlating for the plurality of samples. The remainder of this section describes in more detail the steps of (1) contacting, (2) detecting, and (3) correlating.

1. Contacting

5 The step of contacting assay components such as enzymes, enzyme modulators, substrates, products, and/or binding partners with one another and/or with other species generally comprises any method for bringing any specified combination of these components into functional and/or reactive contact. A preferred method is by mixing and/or forming the materials in solution, although other methods, such as attaching one or more components such as the binding partner to a bead or surface, also may be used, as long as the components retain at least some function, specificity, and/or binding affinity following such attachment. Exemplary apparatus having fluidics capability suitable for contacting or otherwise preparing assay components are described in the following patent applications, which are incorporated herein by reference: U.S. Patent Application Serial No. 09/777,343, filed February 5, 2001; and U.S. Provisional Patent Application Serial No. 60/267,639, filed February 10, 2001.

One of more of the assay components may comprise a sample, which typically takes the form of a solution containing one or more biomolecules that are biological and/or synthetic in origin. The sample may be a biological sample that is prepared from a blood sample, a urine sample, a swipe, or a smear, among others. Alternatively, the sample may be an environmental sample that is prepared from an air sample, a water sample, or a soil sample, among others. The sample typically is aqueous but may contain

biologically compatible organic solvents, buffering agents, inorganic salts, and/or other components known in the art for assay solutions.

The assay components and/or sample may be supported for contact and/or analysis by any substrate or material capable of providing such support. Suitable substrates may include microplates, PCR plates, biochips, and hybridization chambers, among others, where features such as microplate wells and microarray (i.e., biochip) sites may comprise assay sites. Suitable microplates are described in the following U.S. patent applications, which are incorporated herein by reference: Serial No. 08/840,553, filed April 14, 1997; and Serial No. 09/478,819, filed January 5, 2000. These microplates may include 96, 384, 1536, or other numbers of wells. These microplates also may include wells having small ($\leq 50 \mu\text{L}$) volumes, elevated bottoms, and/or frusto-conical shapes capable of matching a sensed volume. Suitable PCR plates may include the same (or a similar) footprint, well spacing, and well shape as the preferred microplates, while possessing stiffness adequate for automated handling and thermal stability adequate for PCR. Suitable microarrays include nucleic acid and polypeptide microarrays, which are described in Bob Sinclair, Everything's Great When It Sits on a Chip: A Bright Future for DNA Arrays, 13 THE SCIENTIST, May 24, 1999, at 18, which is incorporated herein by reference. Suitable hybridization chambers are described in PCT Patent Application Serial No. PCT/US99/03678, filed February 19, 1999, which is incorporated herein by reference.

2. Detecting

The step of detecting a response indicative of the extent of binding generally comprises any method for effectuating such detection, including detecting and/or

quantifying a change in, or an occurrence of, a suitable parameter and/or signal. The method may include luminescence and/or nonluminescence methods, and heterogeneous and/or homogeneous methods, among others.

Luminescence and nonluminescence methods may be distinguished by whether they involve detection of light emitted by a component of the sample. Luminescence assays involve detecting light emitted by a luminescent compound (or luminophore) and using properties of that light to understand properties of the compound and its environment. A typical luminescence assay may involve (1) exposing a sample to a condition capable of inducing luminescence from the sample, and (2) measuring a detectable luminescence response indicative of the extent of binding between the member of interest and a corresponding binding partner. Most luminescence assays are based on photoluminescence, which is luminescence emitted in response to absorption of suitable excitation light. However, luminescence assays also may be based on chemiluminescence, which is luminescence emitted in response to chemical excitation, and electrochemiluminescence, which is luminescence emitted in response to electrochemical energy. Suitable luminescence assays include, among others, (1) luminescence intensity, which involves detection of the intensity of luminescence, (2) luminescence polarization, which involves detection of the polarization of light emitted in response to excitation by polarized light, and (3) luminescence energy transfer, which involves detection of energy transfer between a luminescent donor and a suitable acceptor. These and other luminescence assays are described below in Example 14 and materials cited therein. Nonluminescence assays involve using a detectable response other than light emitted by the sample, such as

absorption, scattering, and/or radioactivity, among others. These and other nonluminescence assays are described in the following materials, which are incorporated herein by reference: U.S. Patent Application Serial No. 09/765,869, filed January 19, 2001; and Joseph R. Lakowicz, Principles of Fluorescence Spectroscopy (2nd ed. 1999).

5 The detectable luminescence response generally comprises a change in, or an occurrence of, a luminescence signal that is detectable by direct visual observation and/or by suitable instrumentation. Typically, the detectable response is a change in a property of the luminescence, such as a change in the intensity, polarization, energy transfer, lifetime, and/or excitation or emission wavelength distribution of the luminescence. The
10 detectable response may be simply detected, or it may be quantified. A response that is simply detected generally comprises a response whose existence merely is confirmed, whereas a response that is quantified generally comprises a response having a quantifiable (e.g., numerically reportable) value such as an intensity, polarization, and/or other property. In luminescence assays, the detectable response may be generated directly
15 using a luminophore associated with an assay component actually involved in binding such as A* or BP, or indirectly using a luminophore associated with another (e.g., reporter or indicator) component. Suitable methods and luminophores for luminescently labeling assay components are described in the following materials, which are
20 incorporated herein by reference: Richard P. Haugland, Handbook of Fluorescent Probes and Research Chemicals (6th ed. 1996); U.S. Patent Application Serial No. 09/813,107, filed March 19, 2001; and U.S. Patent Application Serial No. 09/815,932, filed March 23, 2001.

Heterogeneous and homogeneous methods may be distinguished by whether they involve sample separation before detection. Heterogeneous methods generally require bulk separation of bound and unbound species. This separation may be accomplished, for example, by washing away any unbound species following capture of the bound species on a solid phase, such as a bead or microplate surface labeled with a tricationic metal ion or other suitable binding partner. The extent of binding then can be determined directly by measuring the amount of captured bound species and/or indirectly by measuring the amount of uncaptured unbound species (if the total amount is known). Homogeneous methods, in contrast, generally do not require bulk separation but instead require a detectable response such as a luminescence response that is affected in some way by binding or unbinding of bound and unbound species without separating the bound and unbound species. Homogeneous assays typically are simpler to perform but more complicated to develop than heterogeneous assays.

3. Correlating

The step of correlating generally comprises any method for correlating the extent of binding with the extent of modification of the assay component being analyzed, and/or with the presence and/or activity of an enzyme that affects the modification. The nature of this step depends in part on whether the detectable response is simply detected or whether it is quantified. If the response is simply detected, it typically will be used to evaluate the presence of a component such as a substrate, product, and/or enzyme, or the presence of an activity such as an enzyme or modulator activity. In contrast, if the response is quantified, it typically will be used to evaluate the presence and/or quantity of

a component such as a substrate, product, and/or enzyme, or the presence and/or activity of a component such as an enzyme or modulator.

The correlation generally may be performed by comparing the presence and/or magnitude of the response to another response (e.g., derived from a similar measurement of the same sample at a different time and/or another sample at any time) and/or a calibration standard (e.g., derived from a calibration curve, a calculation of an expected response, and/or a luminescent reference material). Thus, for example, in a polarization assay for cyclic nucleotide concentration, the cyclic nucleotide concentration in an unknown sample may be determined by matching the polarization measured for the unknown with the cyclic nucleotide concentration corresponding to that polarization in a calibration curve generated under similar conditions by measuring polarization as a function of cyclic nucleotide concentration. More generally, the following table shows representative qualitative changes in the indicated detectable luminescence response upon binding between A* and BP following a forward reaction $A \rightarrow A^*$.

Label on A*	Label on BP	Intensity (Luminophore)	Intensity (Acceptor)	FP (Luminophore)	ET (Lum. \rightarrow Acc.)
Luminophore	—			Increases	
—	Luminophore			Increases	
Luminophore	Quencher	Decreases			
Quencher	Luminophore	Decreases			
Luminophore	Acceptor	Decreases	Increases	Decreases	Increases
Acceptor	Luminophore	Decreases	Increases		Increases

This reaction is representative of a phosphorylation reaction performed by a kinase or a decyclization reaction performed by a PDE, assuming that the binding partner binds to the (noncyclized) phosphorylated species. Similarly, the following table shows

representative qualitative changes in the indicated detectable luminescence response upon binding of A* and BP following the reverse reaction $A^* \rightarrow A$.

Label on A*	Label on BP	Intensity (Luminophore)	Intensity (Acceptor)	FP (Luminophore)	ET (Lum. \rightarrow Acc.)
Luminophore	—			Decreases	
—	Luminophore			Decreases	
Luminophore	Quencher	Increases			
Quencher	Luminophore	Increases			
Luminophore	Acceptor	Increases	Decreases	Increases	Decreases
Acceptor	Luminophore	Increases	Decreases		Decreases

- 5 This reaction is representative of a dephosphorylation reaction performed by a phosphatase or a cyclization reaction performed by a cyclase, assuming again that the binding partner binds to the (noncyclized) phosphorylated species.

3. Examples

The following examples describe without limitation further aspects of the invention. These aspects include (1) the ability of binding partners such as tricationic metal ions to bind specifically to phosphorylated species such as phosphopeptides and nucleotides, and (2) the use of such binding in assays for enzymes and other agents involved in phosphorylation and dephosphorylation (e.g., kinases and phosphatases, respectively) and cyclization and decyclization (e.g., cyclases and PDEs, respectively), among others. These aspects are applicable to a wide variety of enzymes and enzyme substrates and products.

Example 1

This example describes a macromolecular trapping system for use in luminescence polarization and/or energy transfer assays, among others, in accordance with aspects of

the invention. In this system, Ru^{2+} is entrapped in small (~20-30 kDa) synthetic polymer macromolecules (MM), which are obtained from PreSens Precision Sensing (Neuburg/Donau, Germany). These macromolecules are relatively hydrophilic, with carboxyl groups on their surfaces for activation. The MM with the entrapped Ru^{2+} is used as a support to immobilize tricationic metal cations, including Fe^{3+} and Ga^{3+} . Specifically, the chelator imidodiacetic (IDA) acid is linked to the MM using the secondary amine group of IDA and a carboxyl group on the MM. Afterwards, the MM-IDA is incubated with either FeCl_3 or GaCl_3 . The FeCl_3 quenches the luminescence of Ru^{2+} , whereas the GaCl_3 does not. The macromolecule loaded with Fe^{3+} or Ga^{3+} is denoted MM-Fe or MM-Ga, respectively.

The macromolecular trapping system may be used in a variety of kinase, phosphatase, phosphodiesterase, and/or cyclase assays, as described below in Examples 3-5 and 7-9. In an exemplary assay, a kinase enzyme phosphorylates a luminescently labeled kinase substrate, which binds to the metal cations immobilized on the MM. Binding is detected using polarization and/or energy transfer methods, among others, for example, using apparatus and methods as described herein. Binding is detectable using polarization because binding leads to a decrease in substrate mobility and a concomitant increase in the polarization of light emitted by luminophores bound to the substrate. Similarly, binding is detectable using energy transfer because binding leads to a decrease in separation between the luminophores bound to the substrate and the Ru^{2+} immobilized in the MM, and a concomitant increase in energy transfer from the Ru^{2+} (donor) to the luminophore (acceptor).


This approach may be extended by various modifications and/or substitutions. For example, in polarization assays, the Ru^{2+} may be omitted, if desired. In energy transfer assays, the Ru^{2+} may be replaced by any energy transfer partner, as long as the energy transfer partner supported by the MM is capable of energy transfer to or from a complementary energy transfer partner supported by the species binding to the MM. Exemplary energy transfer partners are described in U.S. Patent Application Serial No. 09/815,932, filed March 23, 2001, which is incorporated herein by reference. Also, the Ru^{2+} or its analog does not need to be encapsulated in the MM. A luminescent species may be attached directly to a suitable Fe^{3+} or Ga^{3+} chelate. In a heterogeneous assay, phosphorylated proteins bound via Ga^{3+} or Fe^{3+} to microplates, particles, or inner surfaces of microfluidic devices may be detected after a wash by measuring luminescence intensity. Such detection can take place either directly on the surfaces or in the solution phase by adding an elution solution such as a phosphate buffer. With other detection methods, such as the laser-scanning method used in fluorometric microvolume assay technology (FMAT™) technology (PE Biosystems, Foster City, California), the bound phosphoproteins can be detected directly on the beads, without the need for washing or separation. Other labels such as enzymes also may be used in the heterogeneous format.

Potential difficulties with this system include (1) interference from compounds (e.g., ATP, free phosphate, EDTA, and possibly primary/secondary amines) that may compete with or otherwise affect the interaction between the metal and the phosphorylated protein, and (2) difficulty in maintaining a pH that preserves the affinity and selectivity of the binding between the metal and phosphorylated protein.

Example 2

This example describes assays for the presence, activity, substrates, and/or products of kinases in accordance with aspects of the invention. Similar assays may be used to analyze phosphatases in which the substrates and products of the kinase reaction become the products and substrates of the phosphatase reaction, respectively.

Kinases catalyze the addition of phosphate groups to appropriate substrates, as shown below:



Thus, the presence and/or activity of a kinase may be detected by a decrease in the concentration of a nonphosphorylated (e.g., polypeptide) substrate and/or by an increase in the concentration of a corresponding phosphorylated product, among others. (The presence and/or activity of a phosphatase may be detected similarly by a decrease in the concentration of a phosphorylated substrate and/or an increase in the concentration of a nonphosphorylated product.) The invention provides among others kinase assays that involve contacting a sample containing a candidate kinase (and optionally a modulator thereof) with a luminescently labeled nonphosphorylated polypeptide having at least one amino acid subject to phosphorylation (such as a tyrosine, serine, and/or threonine) and a binding partner that binds specifically to the phosphorylated polypeptide but not to the nonphosphorylated polypeptide. These assays further involve detecting a response

indicative of the extent of binding between the polypeptide and the binding partner such as luminescence intensity, polarization, and/or energy transfer, and correlating the response with the extent of phosphorylation or nonphosphorylation of the polypeptide, and thus with the activity of the candidate kinase. The binding partner may include a metal ion such as a tricationic metal ion that interacts with the phosphate group on the phosphorylated polypeptide to facilitate the binding reaction. The binding partner also may include a macromolecule, a nanoparticle, a solid phase portion, a quencher, and/or an energy transfer partner complementary to the luminophore on the polypeptide, depending in part on the detection scheme.

Example 3

This example describes experiments to characterize binding between MM-Ga and a fluorescein-labeled di-phosphotyrosine 15-amino-acid peptide tracer denoted tyrosine kinase 1 (TK-1) tracer. These experiments show the utility of the MM-Ga system for detection of phosphorylated tyrosine and the presence and/or activity of tyrosine kinases and phosphatases.

Figure 8 shows the effects of incubating 10 nM TK-1 tracer with different concentrations of MM-GA (total volume = 50 μ L; incubation time = 60 min). These experiments show that the maximum polarization change is more than 200 mP, at least when the MM-Ga and TK-1 tracer are incubated in MES buffer (0.1M MES, pH 5.5, 1.0 M NaCl). This polarization change is at least sufficient for most polarization assays.

Figure 9 shows a dose-response curve for TK-1 calibrator, with 10 nM TK-1 tracer and 1.6 nM (estimated) MM-Ga. The TK-1 calibrator is the same as the TK-1 tracer,

without a fluorescein label. The bound/total ratio is calculated as in Figure 8. These experiments show that the IC₅₀ for the TK-1 calibrator also is around 10 μ M. The IC₅₀ (inhibitory concentration 50%) is the concentration of inhibitor required for 50% inhibition. More generally, the IC₅₀ (or EC₅₀ (effective concentration 50%)) is the drug concentration at which an associated response has decreased (increased) to 50% of the initial response, assuming that the response is a decreasing (increasing) function of drug concentration.

Example 4

This example describes experiments to characterize binding between MM-Ga and the following mono-serine fluorescein-labeled peptide tracer:

fluorescein-Leu-Arg-Arg-Ala-Ser-Leu-Gly

This peptide is termed a “Kemptide,” and the fluorescein-labeled peptide is termed a “fluo-Kemptide.” These experiments use cAMP-dependent protein kinase A (PKA, Promega) as the enzyme and fluo-Kemptide as the substrate. These experiments show the utility of the MM-Ga system for detection of phosphorylated serine and the presence and/or activity of serine/threonine kinases and phosphatases.

Figure 10 shows an endpoint assay for PKA activity with MM-Ga under the following conditions: (1) reaction with enzyme, with MM-Ga; (2) reaction with enzyme, without MM-Ga; (3) reaction without enzyme, with MM-Ga; and (4) reaction without enzyme, without MM-Ga. The assay is performed as follows. First, a mixture is prepared of 20 mM MgCl₂, 0.2 mM ATP, 2 mM NaVO₄, and 100 μ M fluo-Kemptide in a total of

50 μ L 40 mM Tris-HCl (pH 7.4). Second, the reaction is initiated by adding 1.0 μ L of the enzyme PKA to the mixture; for a control reaction, no PKA is added. Third, the reaction is run overnight at room temperature. Fourth, the reaction and control are diluted 1:1000, and 1 μ L of the diluted solution is added to a volume of 49 μ L of MM-Ga solution (approximately 30 nM MM-Ga) in a MES buffer (pH 5.5) in a 384-well plate. Fifth, the plate is incubated at room temperature for 60 min. Finally, the luminescence polarization is measured using an ANALYST™ light-detection platform (Molecular Devices Corporation, Sunnyvale, California). These experiments show that the phosphorylated peptide and the MM-Ga bind to one another specifically, i.e., that the phosphorylated Kemptide and the MM-Ga bind together strongly and that the nonphosphorylated Kemptide and the MM-Ga do not bind together appreciably.

Figure 11 shows a time-course assay for PKA activity with MM-Ga, performed under the reaction conditions of Figure 10. At each time point, 1 μ L of reaction mixture is taken out from the reaction and immediately diluted into a volume of 1000 μ L of MES buffer. Afterwards, 1 μ L of each diluted sample is added to a volume of 49 μ L of MM-Ga solution, and an assay is conducted as described above.

Example 5

Examples 3 and 4 describe homogeneous assays in which metal ions (e.g., Ga^{3+}) immobilized on macromolecules system bind selectively to phosphorylated peptides generated in a kinase reaction. These assays may be used to monitor the time course

and/or end point of a kinase (and/or phosphatase) reaction using various luminescence methods, including luminescence polarization.

This example describes a heterogeneous kinase assay in accordance with aspects of the invention. Here, the feasibility of using metal-coated plates in the development of generic kinase assays is demonstrated with a commercial Ni^{2+} -coated plate (Pierce, Rockford, Illinois), in which the Ni^{2+} is replaced with Ga^{3+} . Specifically, 200 μL of a 0.5 M EDTA-containing solution is added to each well of a 96-well Ni^{2+} -coated plate, and the plate is incubated at room temperature for 1 hour. The process is repeated two more times to remove at least substantially all of the Ni^{2+} from the plate. The plate then is washed 3 times with 10 mM Tris buffer (pH 7.4). Next, 200 μL of a 0.1 M GaCl_3 solution is added to each well of the plate, and the plate is incubated overnight at room temperature. The plate is washed three times before being used in a kinase assay. This procedure effectively converts the walls of the plate into assay surfaces capable of binding a phosphorylated substrate but not a nonphosphorylated substrate.

Figure 12 shows results from a kinase assay and an associated control assay. The kinase reaction is set up as described previously, using PKA as the enzyme and fluorescein-Kemptide as the substrate. At each time point, 1 μL is taken from the reaction and diluted into 1000 μL of MES buffer. Later, a volume of 100 μL of each diluted solution is added to the Ga^{3+} -coated plate or (as a control) an unmodified Ni^{2+} -coated plate and incubated for 1 hour at room temperature. Then, the plate is washed three times, and 100 μL of a 1 M KH_2PO_4 solution is added to elute the bound phosphorylated Kemptide from the plate. The luminescence intensity is measured using an ANALYST™


light-detection platform (Molecular Devices Corporation, Sunnyvale, California), which is set in fluorescence intensity mode and fitted with a medium attenuator. The luminescence may be measured from above and/or below the sample, for example, from below the sample by detecting through a lower surface of the sample well that transmits light. In some embodiments, a blocking reagent such as a quencher may be added to the sample to reduce luminescence (and hence background) from unbound components of the sample.

These experiments show the viability of a heterogeneous assay format and the specificity of binding to the tricationic versus dicationic metal ion. The heterogeneous assay format offers many of the advantages of the homogenous assays, including its applicability in principle to any kinase regardless of its substrate specificity. This may save assay developers 3 to 6 months of time and effort in making antibodies that recognize specifically a phosphorylated version of an amino acid sequence. The lack of availability of such special antibodies often is the major obstacle in the development of nonradioactive kinase assays. The heterogeneous assay format also allows for simple detection using luminescence intensity, without requiring polarizers or selection of complementary energy transfer pairs.

Example 6

This example describes assays for the presence, activity, substrates, and/or products of phosphodiesterases in accordance with aspects of the invention. Similar assays may be used to analyze cyclases in which the substrate of the phosphodiesterase reaction becomes the product of the cyclase reaction.

Phosphodiesterases (PDEs) catalyze the decyclization of cyclic nucleotides to the corresponding noncyclized nucleotide monophosphate, as shown below:



Thus, the presence and/or activity of a PDE may be detected by a decrease in the concentration of a cyclic nucleotide (cNMP) substrate and/or by an increase in the concentration of a corresponding uncyclized nucleotide monophosphate (NMP) product.

(The presence and/or activity of a cyclase may be detected similarly by a decrease in the concentration of a nucleotide triphosphate substrate and/or by an increase in the concentration of a corresponding cyclic nucleotide.) The invention provides among others PDE assays that involve contacting a sample containing a candidate PDE (and optionally a modulator thereof) with a luminescently labeled cyclic nucleotide and a binding partner that binds specifically to the corresponding uncyclized nucleotide monophosphate but not to the cyclic nucleotide. The binding partner may include one or more of the attributes described above, such as a tricationic metal M^{3+} (e.g., Al^{3+} , Ga^{3+} ,

and/or Fe^{3+}) capable of binding an uncyclized phosphate group but not a cyclized phosphate group, and optionally an energy transfer partner and/or quencher. PDE activity may be detected by an increase in NMP binding using any technique capable of measuring such an increase, including luminescence polarization, luminescence resonance energy transfer, luminescence intensity, and/or nonluminescence and/or heterogeneous techniques, among others. For example, PDE activity may be detected

following NMP binding by (1) an increase in luminescence polarization (assuming that the lifetime and rotational correlation time of the binding partner are selected so that binding of the NMP to the binding partner measurably decreases the rotational correlation time of the NMP), (2) an increase in luminescence resonance energy transfer (assuming that the binding partner is associated with a suitable energy transfer partner), and/or (3) a decrease in luminescence intensity (assuming that the binding partner is associated with a suitable luminescence quencher).

The assays may include (1) contacting a sample containing a candidate PDE (and/or other cell-signaling component) with a luminescently labeled cyclic nucleotide and a binding partner capable of distinguishing between the cyclic nucleotide and the corresponding nucleotide monophosphate, (2) illuminating the sample with light capable of inducing luminescence in the sample, (3) measuring a property of the luminescence transmitted from the sample, and (4) correlating the property with the presence and/or activity of the cyclic nucleotide and/or the corresponding nucleotide monophosphate and hence the presence and/or activity of an associated enzyme.

The invention also provides methods for identifying modulators such as agonists and inhibitors of receptors and/or enzymes involved in the production and/or regulation of cell-signaling molecules, such as the hydrolysis of cyclic nucleotides. The methods may include looking for the effects of a modulator by conducting a method for determining the concentration of a cyclic nucleotide and/or the corresponding nucleotide monophosphate in both the presence and absence of the putative modulator. For example, in a polarization assay in which PDE activity leads to an increase in polarization, a

decrease in the measured extent of polarization of the emitted light in the presence of the putative modulator identifies the putative modulator as an inhibitor of the receptor or enzyme, and an increase in the measured extent of polarization in the presence of the putative modulator identifies the putative modulator as an agonist of the receptor or enzyme.

Example 7

This example describes end-point and time-course assays for PDE 5 in accordance with aspects of the invention, showing in part the utility of the MM-Ga system in PDE assays. These assays use the following components, among others: (1) cGMP-specific PDE (type V, Calbiochem, La Jolla, California), (2) *N*-methylantraniloyl (MANT) cGMP substrate (Molecular Probes, Eugene, Oregon), and (3) MM-Ga, as described in Example 1. MANT is a compact blue-fluorescing luminophore that attaches to the cGMP via the ribose ring of the cGMP. These assays show the utility of the MM-Ga system for detection of noncyclized GMP and the presence and/or activity of cGMP-specific PDEs.

Figure 13 shows results of an end-point assay. Here, 1 μ L (50 units) of cGMP specific PDE is added to 50 μ L of 5 μ M MANT-cGMP in a HEPES buffer (pH 7.5). The tube is incubated at room temperature for 60 minutes. Then, 10 μ L of the reaction mixture is added to 40 μ L of MES/BSA buffer (pH 5.5) containing approximately 0.8 μ M MM-Ga. The resulting mixture is incubated at room temperature for 30 minutes. Then, the luminescence polarization is measured (for MANT, excitation 360 nm, emission 480 nm) using an ANALYST™ light-detection platform (Molecular Devices

Corporation, Sunnyvale, California). Results correspond to the following conditions:

(1) reaction with enzyme, with MM-Ga, (2) reaction with enzyme, without MM-Ga
(3) reaction without enzyme, with MM-Ga, and (4) reaction without enzyme, without
MM-Ga. These experiments show that the cyclic GMP and the MM-Ga bind to one
5 another specifically.

Figure 14 shows results of a time-course assay. Here, a 50- μ L solution containing
100 μ M MANT-cGMP and 100 units of PDE in HEPES buffer (pH 7.5) is incubated at
room temperature. At each time point, 2 μ L of reaction mixture is removed from the tube
and diluted into 200 μ L of MES/BSA buffer (pH 5.5). After 2 hours, 45 μ L of each
diluted reaction solution is mixed with 5 μ L of MM-Ga (approx. 6.4 μ M) and incubated
at room temperature for 30 minutes before the fluorescence polarization is measured.

Example 8

This example describes alternative PDE assays in accordance with aspects of the
invention. These assays are presented in a homogenous, nonradioactive format using a
carboxyfluorescein labeled cGMP substrate. The assay also may be used in a
heterogeneous format and/or with an alternative luminescent cGMP and/or cAMP. These
assays further show the utility of the MM-Ga system for detection of noncyclized GMP
and the presence and/or activity of cGMP-specific PDEs, including the use of a different
luminophore than the MANT of Example 7.

Figure 15 shows results of a time-course assay conducted using fluorescein-cGMP
and the PDE and binding partner of Example 7. Here, 2.0 μ M fluorescein-cGMP is

incubated with 0.5 unit of PDE (V) in a buffer containing 40 mM MOPS (pH 7.5), 0.5 mM EDTA, 15 mM MgCl₂, and 0.15 mg/mL BSA in a total volume of 50 μL. At each time point, 1 μL of the reaction mixture is removed and diluted into 200 μL of MES buffer (pH 5.5), and the diluted solution is placed on ice. After the reaction, 25 μL of the diluted solution is mixed with an equal volume of a MM-Ga solution, and incubated at room temperature for 30 minutes before the luminescence polarization value is measured.

Figure 16 shows results of an inhibition assay using the components of Figure 15. Here, the assay was used to measure the IC₅₀ of the known PDE (V) inhibitor, Zaprinast, using 0.5 μM fluorescein-cGMP and a reaction time of 30 min. These experiments show that the IC₅₀ is about 0.1 μM, in reasonable agreement with the literature value of about 0.3 μM determined using a radioactive assay with ³H-cGMP as the substrate.

Example 9

This example describes several aspects of the invention, including (1) use of Ga³⁺-coated nanoparticles as the binding component in the assay, (2) applications to the detection of PDE 4 enzyme, with fluorescein-labeled cAMP as substrate, and (3) applications to the detection of PDE 1 enzyme, with both fluorescein-labeled cAMP and fluorescein-labeled cGMP as substrates.

As discussed in Example 1, synthetic polymer macromolecules (MM) can be substituted with other materials that have a high molecular weight and that tricationic cations (i.e., Fe³⁺, Ga³⁺) can be immobilized on. Here, we use selected nanoparticles, including polystyrene nanoparticles having an average diameter of about 40 nm. The

nanoparticles are from Bangs Laboratory (Fisher, Indiana), and are modified after acquisition from the vendor to attach Ga^{3+} on the surfaces of the particles.

Figure 17 shows the detection of PDE 4 activity using a fluorescein-labeled cAMP (FL-cAMP) substrate. PDE 4 was obtained from Dr. Macro Conti at Stanford University.



5 In this assay, 10 μL of a solution containing 40 nM of FL-cAMP is mixed with 10 μL of a series of solutions containing various concentrations of PDE 4 in a black 384-well plate. The mixture is incubated at room temperature for 45 min, and then 60 μL of a solution containing 0.16 mg/mL of the modified nanoparticles is added. The new mixture is incubated for 30 min, and then the luminescence polarization is measured.

10 Figure 18 shows similar results using PDE 5 (Calbiochem, La Jolla, CA) as the enzyme and a fluorescein-labeled cGMP (FL-cGMP) as the substrate under the conditions of Figure 17.

15 Figure 19 shows similar results using PDE 1 (Sigma, St. Louis, MO) as the enzyme and both FL-cAMP and FL-cGMP as substrates under the conditions of Figure 17. PDE 1 is another isozyme in the PDE family of enzymes, which acts on both FL-cAMP and FL-cGMP. The PDE 1 used here is activated according to the vendor's instructions.

Example 10

20 This example shows representative tracers for use in cyclic nucleotide assays, particularly luminescence-polarization-based cyclic nucleotide assays. General structures for such tracers are shown below for (A) cAMP and (B) cGMP:



Here, X and R1 represent linkers, which optionally and independently may be present or absent, and Fl represents a reporter species. X may include among others any alkyl, allyl, or aryl linker with ester or ether bonds to the cyclic nucleotide, including $-\text{OC}(=\text{O})-\text{CH}_2\text{CH}_2\text{C}(=\text{O})-$. R1 may be any linker joining FL to the nucleotide, directly, or indirectly through X, including a rigid linker having (two) reactive groups for coupling, one to FL and one to the nucleotide. For example, R1 may be a diamino-alkyl, -cycloalkyl, -aryl, or -allyl group, or a dihydroxy group that forms an amide or ester, respectively, with the groups X and Fl. Fl may include any suitable reporter species, such as a luminophore for luminescence assays or an isotope for radioassays. For example, Fl

may include a fluorescein or rhodamine that forms a thiourea, ester, or amide bond with the group X. Preferred structures include 1,2 and 1,4-diaminocyclohexyl-linked tracers, as described in U.S. Patent Application Serial No. 09/768,661, filed January 23, 2001, which is incorporated herein by reference.

5 **Example 11**

10 This example describes methods and kits for detecting phosphate modifications and/or associated enzymes and modulators in whole cells. The methods generally comprise growing cells under desired conditions, lysing the cells, incubating the cells before and/or after lysis with one or more reagents, and detecting the presence, quantity, and/or activity of species and/or reactions of interest. The kits generally comprise collections of reagents and/or other materials of interest, including substrates, binding partners, and/or lysis buffers, among others. The methods and kits are described greater detail in the context of cyclic nucleotide assays for adherent and suspended cells in Examples 8 and 9 of U.S. Patent Application Serial No. 09/768,661, filed January 23, 2001, which is incorporated herein by reference.

15 **Example 12**

This example describes miscellaneous applications and other uses for the various assays described herein.

20 The applications include detecting any of the modifications, enzymes, and/or modulators identified herein and/or in the following U.S. patent applications, which are incorporated herein by reference: Serial No. 09/768,661, filed January 23, 2001; and Serial No. 09/596,444, filed June 19, 2000. The modifications include phosphorylation,

dephosphorylation, cyclization, and/or decyclization, among others, as described above.

The enzymes include kinases, phosphatases, cyclases, and/or phosphodiesterases, among others, including variants such as isoenzymes thereof. For example, the cyclases include adenylyl cyclase and guanylyl cyclase, among others, and the phosphodiesterases include PDE 1 through PDE 10, among others. The modulators include modulators of these enzymes, among others. For example, the cyclase modulators include forskolin and ODQ, among others, and the phosphodiesterase modulators include cilostamide, dipyridamole, EHNA hydrochloride, etazolate hydrochloride, MBCQ, MMPX, MY-5445, Ro 20-1724, rolipram, siguazodan, vinpocetine, and Zaprinast, among others.

The applications also include combining assays for different modifications, enzymes, and/or modulators to form integrated assays, for example, by combining a phosphorylation assay and a cyclization assay to study signaling mechanisms involving multiple cell-signaling pathways.

Example 13

This example describes kits for use in performing assays in accordance with aspects of the invention. The kits may include substrates and/or binding partners for performing the assays described herein. These substrates and/or binding partners may include luminophores, quenchers, and/or energy transfer partners, among others. The kits also may include sample holders such as microplates or biochips that have been treated to act as binding partners. The kits optionally may include additional reagents, including but not limited to buffering agents, luminescence calibration standards, enzymes, enzyme substrates, nucleic acid stains, labeled antibodies, or other additional luminescence

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

detection reagents. The substrates, binding partners, and/or additional reagents optionally are present in pure form, as concentrated stock solutions, or in prediluted solutions ready for use in the appropriate energy transfer assay. Typically, the kit is designed for use in an automated and/or high-throughput assay, and so is designed to be fully compatible with microplate readers, microfluidic methods, and/or other automated high-throughput methods.

Example 14

This example describes exemplary luminescence assays. Further aspects of these assays as well as additional luminescence assays and apparatus for performing luminescence assays are described in the following materials, which are incorporated herein by reference: U.S. Patent No. 6,097,025, issued September 24, 1998; U.S. Patent Application Serial No. 09/349,733, filed July 8, 1999; U.S. Provisional Patent Application Serial No. 60/267,639, filed February 10, 2001; and Joseph R. Lakowicz, Principles of Fluorescence Spectroscopy (2nd ed. 1999).

Luminescence, as defined above, is the emission of light from excited electronic states of atoms or molecules, including photoluminescence, chemiluminescence, and electrochemiluminescence, among others. Luminescence may be used in a variety of assays, including (A) intensity assays, (B) polarization assays, and (C) energy transfer assays, among others.

A. Intensity Assays

Luminescence intensity assays involve monitoring the intensity (or amount) of light emitted from a composition. The intensity of emitted light will depend on the

extinction coefficient, quantum yield, and number of luminescent analytes in the composition, among others. These quantities, in turn, will depend on the environment of the analyte, among others, including the proximity and efficacy of quenchers and energy transfer partners. Thus, luminescence intensity assays may be used to study binding reactions, among other applications.

B. Polarization Assays

Luminescence polarization assays involve the absorption and emission of polarized light. Here, polarization refers to the direction of the light's electric field, which generally is perpendicular to the direction of the light's propagation. In a luminescence polarization assay, specific molecules within a composition are labeled with one or more luminophores. The composition then is illuminated with polarized excitation light, which preferentially excites luminophores having absorption dipoles aligned parallel to the polarization of the excitation light. These molecules subsequently decay by preferentially emitting light polarized parallel to their emission dipoles. The extent of polarization of the total emitted light depends on the extent of molecular reorientation during the time interval between luminescence excitation and emission, which is termed the luminescence lifetime, τ . In turn, the extent of molecular reorientation depends on the luminescence lifetime and the size, shape, and environment of the reorienting molecule. Thus, luminescence polarization assays may be used to quantify binding reactions and enzymatic activity, among other applications. In particular, molecules commonly rotate (or "tumble") via diffusion, with a rotational correlation time τ_{rot} that is proportional to their volume, or the cube of their radius of gyration. (This cubic dependence on radius

makes polarization assays very sensitive to binding.) Thus, during their luminescence lifetime, relatively large molecules will not reorient significantly, so that their total luminescence will be relatively polarized. In contrast, during the same time interval, relatively small molecules will reorient significantly, so that their total luminescence will be relatively unpolarized.

The relationship between polarization and intensity is expressed by the following equation:

$$P = \frac{I_{||} - I_{\perp}}{I_{||} + I_{\perp}} \quad (1)$$

Here, P is the polarization, $I_{||}$ is the intensity of luminescence polarized parallel to the polarization of the excitation light, and I_{\perp} is the intensity of luminescence polarized perpendicular to the polarization of the excitation light. P generally varies from zero to one-half for randomly oriented molecules (and zero and one for aligned molecules). If there is little rotation between excitation and emission, $I_{||}$ will be relatively large, I_{\perp} will be relatively small, and P will be close to one-half. (P may be less than one-half even if there is no rotation; for example, P will be less than one-half if the absorption and emission dipoles are not parallel.) In contrast, if there is significant rotation between absorption and emission, $I_{||}$ will be comparable to I_{\perp} , and P will be close to zero. Polarization often is reported in milli-P units ($1000 \times P$), which for randomly oriented molecules will range between 0 and 500, because P will range between zero and one-half.

Polarization also may be described using other equivalent quantities, such as anisotropy. The relationship between anisotropy and intensity is expressed by the following equation:

$$r = \frac{I_{||} - I_{\perp}}{I_{||} + 2I_{\perp}} \quad (2)$$

5 Here, r is the anisotropy. Polarization and anisotropy include the same information, although anisotropy may be more simply expressed for systems containing more than one luminophore. In the description and claims that follow, these terms may be used interchangeably, and a generic reference to one should be understood to imply a generic reference to the other.

The relationship between polarization and rotation is expressed by the Perrin equation:

$$\left(\frac{1}{P} - \frac{1}{3}\right) = \left(\frac{1}{P_0} - \frac{1}{3}\right) \cdot \left(1 + \frac{\tau}{\tau_{rot}}\right) \quad (3)$$

Here, P_0 is the polarization in the absence of molecular motion (intrinsic polarization), τ is the luminescence lifetime (inverse decay rate) as described above, and τ_{rot} is the rotational correlation time (inverse rotational rate) as described above.

The Perrin equation shows that luminescence polarization assays are most sensitive when the luminescence lifetime and the rotational correlation time are similar. Rotational correlation time is proportional to molecular weight, increasing by about 1 nanosecond for each 2,400 dalton increase in molecular weight (for a spherical molecule). For shorter lifetime luminophores, such as fluorescein, which has a

luminescence lifetime of roughly 4 nanoseconds, luminescence polarization assays are most sensitive for molecular weights less than about 40,000 daltons. For longer lifetime probes, such as Ru(bpy)₂dcbpy (ruthenium 2,2'-dibipyridyl 4,4'-dicarboxyl-2,2'-bipyridine), which has a lifetime of roughly 400 nanoseconds, luminescence polarization
5 assays are most sensitive for molecular weights between about 70,000 daltons and 4,000,000 daltons.

Luminescence polarization assays may be used in a variety of formats. In one format, the concentration of an analyte in solution can be measured by supplying a labeled tracer that competes with the analyte for a binding moiety, particularly a binding moiety larger than the labeled tracer. In this “competitive” format, the concentration of the analyte is inversely correlated with the enhancement of luminescence polarization in the light emitted by the tracer when it competitively binds the common moiety. In another format, the concentration of a target can be measured by supplying a labeled tracer that is capable of binding the target. In this case, the enhancement of polarization is a direct measure of the concentration of target. The target further may be, for example, an activated receptor, where activation can be indirectly measured by the directly measured concentration of a generated molecule or by its binding to labeled tracer *per se*.

C. Energy Transfer Assays

Energy transfer is the transfer of luminescence energy from a donor
20 luminophore to an acceptor without emission by the donor. In energy transfer assays, a donor luminophore is excited from a ground state into an excited state by absorption of a photon. If the donor luminophore is sufficiently close to an acceptor, excited-state energy

may be transferred from the donor to the acceptor, causing donor luminescence to decrease and acceptor luminescence to increase (if the acceptor is luminescent). The efficiency of this transfer is very sensitive to the separation R between donor and acceptor, decaying as $1/R^6$. Energy transfer assays use energy transfer to monitor the proximity of donor and acceptor, which in turn may be used to monitor the presence or activity of an analyte, among others.

Energy transfer assays may focus on an increase in energy transfer as donor and acceptor are brought into proximity. These assays may be used to monitor binding, as between two molecules X and Y to form a complex $X:Y$. Here, colon ($:$) represents a noncovalent interaction. In these assays, one molecule is labeled with a donor D , and the other molecule is labeled with an acceptor A , such that the interaction between X and Y is not altered appreciably. Independently, D and A may be covalently attached to X and Y , or covalently attached to binding partners of X and Y .

Energy transfer assays also may focus on a decrease in energy transfer as donor and acceptor are separated. These assays may be used to monitor cleavage, as by hydrolytic digestion of doubly labeled substrates (peptides, nucleic acids). In one application, two portions of a polypeptide are labeled with D and A , so that cleavage of the polypeptide by a protease such as an endopeptidase will separate D and A and thereby reduce energy transfer. In another application, two portions of a nucleic acid are labeled with D and A , so that cleave by a nuclease such as a restriction enzyme will separate D and A and thereby reduce energy transfer.

Energy transfer between D and A may be monitored in various ways. For example, energy transfer may be monitored by observing an energy-transfer induced decrease in the emission intensity of D and increase in the emission intensity of A (if A is a luminophore). Energy transfer also may be monitored by observing an energy-transfer induced decrease in the lifetime of D and increase in the apparent lifetime of A.

In a preferred mode, a long-lifetime luminophore is used as a donor, and a short-lifetime luminophore is used as an acceptor. Suitable long-lifetime luminophores include metal-ligand complexes containing ruthenium, osmium, etc., and lanthanide chelates containing europium, terbium, etc. In time-gated assays, the donor is excited using a flash of light having a wavelength near the excitation maximum of D. Next, there is a brief wait, so that electronic transients and/or short-lifetime background luminescence can decay. Finally, donor and/or acceptor luminescence intensity is detected and integrated. In frequency-domain assays, the donor is excited using time-modulated light, and the phase and/or modulation of the donor and/or acceptor emission is monitored relative to the phase and/or modulation of the excitation light. In both assays, donor luminescence is reduced if there is energy transfer, and acceptor luminescence is observed only if there is energy transfer.

Example 15

This example shows assays with improved signals, signal-to-noise ratios, and/or signal-to-background ratios.

Signal may be enhanced in several ways, including (1) using a high color temperature light source, such as a xenon arc lamp, in a continuous illumination mode,

(2) using a dichroic or multi-dichroic beamsplitter, and/or (3) using a sample holder whose shape is “matched” to the shape of the optical beam of the instrument, especially if the sample holder is elevated to bring the sample closer to a detector. The high color temperature light source increases the number of usable photons, which is important because the lower limit of the signal-to-noise ratio is set by the square root of the total number of photons collected in the measurement. These enhancements are described in more detail in the following U.S. Patent Applications, which are incorporated herein by reference: Serial No. 09/349,733, filed July 8, 1999; Serial No. 09/478,819, filed January 5, 2000; and Serial No. 09/494,407, filed January 28, 2000.

Signal-to-noise ratios can be enhanced at least in part by increasing signals, for example, by using the techniques described in the previous paragraph.

Signal-to-background ratios can be enhanced in several ways, including (1) using confocal optical systems having a sensed volume to avoid luminescence from the microplate walls, (2) selecting a microplate or other substrate that increases the signal and reduces the luminescent background from materials in the microplate, (3) selecting the light sources, luminescence filters, optics, signal collection electronics, and mechanical system used in the luminescence detection optical system for maximum signal-to-background ratio, and (4) utilizing signal processing, background subtraction, and luminescence lifetime techniques, particularly FLAME™ methodology for background reduction, as described below. These enhancements are described in more detail in the following U.S. patent and U.S. patent applications, which are incorporated herein by reference: Patent No. 6,071,748, issued April 17, 1998; Serial No. 09/349,733, filed July

8, 1999; Serial No. 09/478,819, filed January 5, 2000; and Serial No. 09/494,407, filed January 28, 2000.

Example 16

5 This example shows mechanisms for increasing the change in polarization that accompanies a change in binding, so that the change in binding can be measured more easily. These mechanisms may be used in any of the assays described here involving luminescently labeled species, such as labeled cyclic nucleotides and labeled nonhydrolyzable GTP analogs, among others.

13 24455-0474
The change in polarization upon binding can be increased by making any linker between the luminophore and the labeled species (e.g., the cyclic nucleotide or GTP analog) as short and/or rigid as possible, while maintaining relevant substrate properties for the enzymes involved in the assay. Short and/or rigid linkers will restrict luminophore motion relative to the labeled species, reducing the "propeller effect" so that the luminophore more accurately reports the motion of both the free and bound labeled species. The rigidity of the linker may be increased by avoiding using hexanoic acid linkers, which typically are long and flexible, and by using cyclic linkers and amide groups in place of methylene groups, among other mechanisms.

20 The change in polarization upon binding also can be increased by including an appropriately positioned energy transfer acceptor on the binding partner, so that energy transfer will occur from the luminophore to the acceptor upon incorporation. Such energy transfer will shorten the lifetime of the luminophore, thereby increasing its polarization (because polarization varies inversely with lifetime, all else being equal).

5 The change in polarization upon binding also can be increased by decreasing the mobility of the binding partner for the labeled species. Mobility can be decreased by increasing the size of the binding partner, either directly or by forming a complex with a mass label. Suitable mass labels include other molecules and beads, among others. The use of mass labels is described in detail in U.S. Patent Application Serial No. 09/768,742, filed Jan. 23, 2001, which is incorporated herein by reference. Mobility also can be decreased by attaching the binding partner to a surface, such as the surface of a sample holder. Attachment to other molecules, beads, and/or surfaces may be accomplished using any of a number of well-known reactive groups.

10 The assays provided by the invention may have advantages over prior assays for detecting molecular modifications. The existence and/or identity of these advantages will depend on such as (but not always requiring) one or more of the following. First, they may be used without radioactivity. Second, they may be homogenous, so that they do not require physical separation steps or wash steps. Third, they may have stable endpoints, so that results are relatively insensitive to the timing of any measurement or detection steps. Fourth, they may be sensitive, so that picomolar amounts of cyclic nucleotides may be detected. Fifth, they may be used with solution and cell-based samples.

15 The disclosure set forth above encompasses multiple distinct inventions with independent utility. Although each of these inventions has been disclosed in its preferred form(s), the specific embodiments thereof as disclosed and illustrated herein are not to be considered in a limiting sense, because numerous variations are possible. The subject matter of the inventions includes all novel and nonobvious combinations and

subcombinations of the various elements, features, functions, and/or properties disclosed herein. The following claims particularly point out certain combinations and subcombinations regarded as novel and nonobvious and directed to one of the inventions. These claims may refer to "an" element or "a first" element or the equivalent thereof; such claims should be understood to include incorporation of one or more such elements, neither requiring nor excluding two or more such elements. Inventions embodied in other combinations and subcombinations of features, functions, elements, and/or properties may be claimed through amendment of the present claims or through presentation of new claims in this or a related application. Such claims, whether directed to a different invention or to the same invention, and whether broader, narrower, equal, or different in scope to the original claims, also are regarded as included within the subject matter of the inventions of the present disclosure.